AU2022288631A1 - Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same - Google Patents

Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same Download PDF

Info

Publication number
AU2022288631A1
AU2022288631A1 AU2022288631A AU2022288631A AU2022288631A1 AU 2022288631 A1 AU2022288631 A1 AU 2022288631A1 AU 2022288631 A AU2022288631 A AU 2022288631A AU 2022288631 A AU2022288631 A AU 2022288631A AU 2022288631 A1 AU2022288631 A1 AU 2022288631A1
Authority
AU
Australia
Prior art keywords
compound
pyridazin
methoxyphenyl
oxadiazol
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022288631A
Other languages
English (en)
Inventor
Christopher FULLENKAMP
Xiao Liang
John S. Schneekloth
Mo YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2022288631A1 publication Critical patent/AU2022288631A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2022288631A 2021-06-09 2022-06-09 Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same Pending AU2022288631A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208918P 2021-06-09 2021-06-09
US63/208,918 2021-06-09
PCT/US2022/032798 WO2022261296A1 (en) 2021-06-09 2022-06-09 Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same

Publications (1)

Publication Number Publication Date
AU2022288631A1 true AU2022288631A1 (en) 2024-01-18

Family

ID=82492690

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022288631A Pending AU2022288631A1 (en) 2021-06-09 2022-06-09 Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same

Country Status (6)

Country Link
US (1) US20240287054A1 (https=)
EP (1) EP4352054A1 (https=)
JP (1) JP2024522183A (https=)
AU (1) AU2022288631A1 (https=)
CA (1) CA3222837A1 (https=)
WO (1) WO2022261296A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025184571A1 (en) * 2024-03-01 2025-09-04 City Of Hope Pcna inhibitors for the treatment of myc family associated cancers
GB202414345D0 (en) * 2024-09-30 2024-11-13 Mycural Therapeutics Ab New compounds and medical uses thereof
GB202414337D0 (en) * 2024-09-30 2024-11-13 Mycural Therapeutics Ab New compounds and medical uses thereof
GB202414343D0 (en) * 2024-09-30 2024-11-13 Mycural Therapeutics Ab New compounds and medical uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
EP2304366A2 (en) * 2008-05-30 2011-04-06 Foster Wheeler Energia Oy Method of and system for generating power by oxyfuel combustion
US10463649B2 (en) * 2015-06-08 2019-11-05 Texas Tech University System Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors

Also Published As

Publication number Publication date
CA3222837A1 (en) 2022-12-15
JP2024522183A (ja) 2024-06-11
EP4352054A1 (en) 2024-04-17
WO2022261296A1 (en) 2022-12-15
US20240287054A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
US20240287054A1 (en) Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same
CN108314677B (zh) 一种ezh2抑制剂及其用途
JP6789239B2 (ja) Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
CN102906090B (zh) 1-(5-叔丁基-2-苯基-2h-吡唑-3-基)-3-[2-氟-4-(1-甲基-2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-7-基氧基)-苯基]-脲和相关化合物及它们在治疗中的应用
KR20210045998A (ko) 헤테로사이클릭 스피로 화합물 및 암 치료를 위한 그의 사용 방법
KR20200010306A (ko) Kras의 공유적 억제제
WO2020160192A1 (en) Compounds and uses thereof
US11014902B2 (en) MYC G-quadruplex stabilizing small molecules and their use
KR20220133259A (ko) 화합물 및 이의 용도
WO2020160198A1 (en) Compounds and uses thereof
CN110869357A (zh) 化合物及其用于治疗癌症的使用方法
JP2018520195A (ja) 置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用
JP2018513853A (ja) 置換キナゾリン化合物およびその使用方法
JP2016500107A (ja) グルタマーゼ阻害剤およびその使用方法
JP2021504314A (ja) Ｍｙｓｔファミリーヒストンアセチルトランスフェラーゼ阻害剤
JP2026053706A (ja) Ｃｄ２０６モジュレーター、その使用、および調製方法
CN116568671A (zh) 杂环Cullin-RING泛素连接酶化合物及其用途
Song et al. Proteolysis targeting chimera of BI-2536 induces potent dual degradation of PLK1 and BET proteins
JP2006518726A (ja) Ｇ四重鎖ｄｎａ構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用
KR20200035029A (ko) 이질염색질 유전자 억제 저해제
WO2017192228A1 (en) Pak1 inhibitors and uses thereof
US20140073637A1 (en) Amino-substituted-alkyloxy-benzo[e]pyrido[4,3-b]indole derivatives as new potent kinase inhibitors
WO2025017207A1 (en) Inhibitors of smndc1 and their therapeutic use
HK40025458A (en) Covalent inhibitors of kras
HK40025457A (en) Compounds and methods of use thereof for treatment of cancer